May 29, 2023
Chugai Pharmaceutical said on May 26 that it has received a label expansion for FoundationOne Liquid CDx Cancer Genomic Profile as a companion diagnostic for Novartis Pharma’s MET inhibitor Tabrecta (capmatinib). Tabrecta is approved in Japan for the treatment of...read more